Serotonin receptor (various subtypes, including 5-HT1A, 5-HT1B, 5-HT2B, 5-HT4) (5-HT receptor (with specific subtypes e.g., 5-HT1A, 5-HT2B))

Serotonin receptors are a family of G protein-coupled receptors found throughout the central and peripheral nervous systems and are involved in the modulation of neurotransmission, vascular tone, and many physiological and behavioral processes. Ergotamine is a tryptamine-derived ergot alkaloid drug that acts as an agonist or partial agonist at multiple serotonin receptor subtypes, notably 5-HT1B, 5-HT1A, 5-HT2B, and 5-HT4. Ergotamine's primary therapeutic use is in the acute treatment of migraine, where it mediates cerebral vasoconstriction via serotonin receptor activation. However, nonspecific receptor interactions contribute to adverse effects, including cardiovascular risks and potential for drug interactions, particularly serotonin syndrome and valvular heart disease via 5-HT2B receptor activation[1][3][9][10].

Other names

5-hydroxytryptamine receptor5-HT receptorSerotonin GPCR5-HT1A receptor5-HT1B receptor5-HT2B receptor5-HT4 receptor

Agonist or partial agonist (ergotamine acts as an agonist and sometimes partial agonist on several 5-HT receptor subtypes including 5-HT1A, 5-HT1B, 5-HT2B, and 5-HT4) Activation of G protein signaling pathways, leading to inhibition of neurotransmitter release or changes in vascular tone Functional selectivity (biased agonism, where the ligand preferentially activates certain signaling pathways over others)